SILO vs. SNPX, PALI, OPGN, FWBI, SONN, TMDIF, FRTX, KZIA, BIOL, and ALZN
Should you be buying Silo Pharma stock or one of its competitors? The main competitors of Silo Pharma include Synaptogenix (SNPX), Palisade Bio (PALI), OpGen (OPGN), First Wave BioPharma (FWBI), Sonnet BioTherapeutics (SONN), Titan Medical (TMDIF), Fresh Tracks Therapeutics (FRTX), Kazia Therapeutics (KZIA), BIOLASE (BIOL), and Alzamend Neuro (ALZN). These companies are all part of the "medical" sector.
Synaptogenix (NASDAQ:SNPX) and Silo Pharma (NASDAQ:SILO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.
10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 5.6% of Silo Pharma shares are held by institutional investors. 4.3% of Synaptogenix shares are held by insiders. Comparatively, 5.6% of Silo Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Synaptogenix has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.
Silo Pharma has a consensus target price of $10.00, indicating a potential upside of 440.54%. Given Synaptogenix's higher probable upside, analysts clearly believe Silo Pharma is more favorable than Synaptogenix.
In the previous week, Silo Pharma had 2 more articles in the media than Synaptogenix. MarketBeat recorded 2 mentions for Silo Pharma and 0 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.49 beat Silo Pharma's score of 0.00 indicating that Silo Pharma is being referred to more favorably in the news media.
Silo Pharma has higher revenue and earnings than Synaptogenix.
Synaptogenix has a net margin of 0.00% compared to Synaptogenix's net margin of -5,134.79%. Silo Pharma's return on equity of -22.50% beat Synaptogenix's return on equity.
Synaptogenix and Silo Pharma both received 1 outperform votes by MarketBeat users. However, 100.00% of users gave Silo Pharma an outperform vote while only 50.00% of users gave Synaptogenix an outperform vote.
Summary
Silo Pharma beats Synaptogenix on 8 of the 13 factors compared between the two stocks.
Get Silo Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for SILO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SILO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Silo Pharma Competitors List
Related Companies and Tools
